Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Shisong is an Oxford University researcher in the Department of Oncology, and the CTO of Oxford Vacmedix, which has developed a technique to grow overlapping peptides in bacteria, to use for cellular immunity vaccines.

Oxford Vacmedix has raised almost £1 million in funding, and is now looking to raise a second round of around £10 million.  There are two centers, one in Oxford and one in China, working on this technology.

Q: What is your background?  Why are you doing this?
A: I studied medicine in China, and then came to London and Harvard for my PhD and initial post doc post.  I had been involved in immunology in London and the US, and was working on HIV and peptide segments for vaccines when I came to Oxford.  I started looking into ways of producing these overlapping peptide segments, and starting using bacteria as a cheap method.

Read more (Enterprising Oxford website)

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

General Innovation

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies

General Innovation

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.